Know Cancer

forgot password

Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary

Phase 2
18 Years
Not Enrolling
Ovarian Carcinoma, Primary Peritoneal Carcinoma

Thank you

Trial Information

Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary

Patients will be treated with pemetrexed 500 mg/m2 IV and Bevacizumab 15 mg/kg IV every 3
weeks.The patient is treated indefinitely until side effects are deemed severe by the
investigator or until progression. Disease progression is measured every 6 weeks using
RECIST criteria.

Inclusion Criteria:

- Recurrent epithelial ovarian or primary peritoneal carcinoma

- Measurable disease

- At lease 1 target lesion to assess response by RECIST

- GOG performance status 0 or 1

- Recovery from effects of recent surgery, radiotherapy or chemotherapy, must
discontinue hormonal therapy

- Must have had 1 prior platinum based chemotherapeutic regimen for management of
primary disease

- Must have had 1 prior regimen containing a taxane compound

Exclusion Criteria:

- Prior therapy with pemetrexed or bevacizumab

- Serious, non-healing wound, ulcer or bone fracture

- Clinically significant cardiovascular disease

- Active bleeding or pathogenic conditions that carry high risk of bleeding, such as
known bleeding disorder, coagulopathy, or tumor involving major - vessels

- Ascites or other third space fluid which cannot be controlled by drainage

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to day 1 or anticipation of need for major surgical procedure during course of

- History or evidence upon physical exam of CNS disease, including primary brain tumor,
brain mets, seizure not controlled with standard medical therapy, history of
CVA/stroke/TIA, or subarachnoid hemorrhage within 6 mos. of day 1

- Proteinuria

- History of abdominal fistula, GI perforation or intra-abdominal abscess within 6 mo.

- Partial or complete small or large bowel obstruction within 3 mo.

- Life expectancy less than 12 weeks

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the anti-tumor activity of the combination of bevacizumab and pemetrexed as measured by progression-free survival in patients with recurrent epithelial ovarian or primary peritoneal carcinoma

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

David G Mutch, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Washington University School of Medicine


United States: Institutional Review Board

Study ID:

08-0508 / 201102272



Start Date:

June 2008

Completion Date:

December 2012

Related Keywords:

  • Ovarian Carcinoma
  • Primary Peritoneal Carcinoma
  • Carcinoma
  • Ovarian Neoplasms
  • Neoplasms, Glandular and Epithelial



Columbia UniversityNew York, New York  10032-3784
Washington UniversitySt. Louis, Missouri  63110